HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: adc.2006.104638v1 92/6/F503    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Webb, D. Articles by Vyas, P. Search for Related Content PubMed PubMed Citation Articles by Webb, D. Articles by Vyas, P.

Haematology of Down syndrome

¹ Department of Haematology, Great Ormond Street Hospital for Children, London, England
² Department of Haematology, Hammersmith and St Mary’s Hospitals, Imperial College, London, England
³ Department of Haematology and MRC Molecular Haematology Unit, John Radcliffe Hospital and Weatherall Institute of Molecular Medicine, Oxford, England

Correspondence to:
Paresh Vyas, Department of Haematology and MRC Molecular Haematology Unit, John Radcliffe Hospital and Weatherall Institute of Molecular Medicine, Oxford OX3 9DU, England; paresh.vyas{at}imm.ox.ac.uk

ABSTRACT
Down syndrome is a common congenital disorder affecting 1/1000 live births. Newborns and children with Down syndrome may present with many haematological problems. In addition, benign abnormalities of the blood count and blood film, which may manifest at any age, population-based and cancer-based registries and clinical trials suggest there is a 12-fold increased risk of acute lymphoblastic leukaemia in the age group of 5–30 years that rises to 40-fold in children younger than 5 years, and that there is a 150-fold increased risk of acute myeloid leukaemia in children younger than 5 years. There is also a virtually unique predisposition to a transient neonatal leukaemia, known as transient abnormal myelopoiesis. Deaths from leukaemia, in part, account for the excess mortality associated with Down syndrome. This article reviews the clinical presentation and the progress made in the management of these disorders over the past decade. It also briefly considers the recent exciting scientific advances that have potential to transform management of leukaemia in children with Down syndrome and also have implications for management of childhood leukaemia more generally.

Abbreviations: ALL-DS, acute lymphoblastic leukaemia of Down syndrome; MDS, myelodysplastic phase; ML-DS, myeloid leukaemia of Down syndrome; TAM, transient abnormal myelopoiesis